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N-Terminal: S6, 
S9, S15, T18, 
S20
ATM, DNAPK, •	
CK1 
ERKs, ATR, p38 •	
kinase, mTOR, 
Chk1/Chk2, JNK, 
MAPKAP2, Hipk4
Activated by DNA damage, UV light, ionizing radiation, replicative senes-•	
cence, or phosphatidylcholines.
N-terminal phosphorylation causes p53 stabilization by inhibiting the p53-•	
MDM2 interaction.
Knockin mice carrying separate analogs to human Ser18/•	
Ser23 mutation are phenotypically normal. Thymocytes 
from Ser18 mutant mice are susceptible to ionizing 
radiation-induced apoptosis, whereas S23 mutation in ES 
cells and MEFs is dispensable for p53 stabilization and 
activation. Ser18/Ser23 double mutant knockin mice dis-
play reduced apoptosis in thymocytes and develop some 
malignancies.
Very rare mutations reported in human tumors. •	
S33, S37, S36, S 
46, T55, T81
GSK3•	 β, p38 
kinase, ATR, 
DNAPK, JNK, 
AMPKalpha
HIPK2, DYKR2, •	
ERK2, TAF1
Activation by UV light (S33, S37, S46, Thr81), H•	 2O2 treatment (S33), 
γ-radiation, DNA damage (S37), and glucose deprivation (Ser46).
Phosphorylation leads to stabilization and promotes p53 transcriptional •	
activity to regulate p53-mediated cell-cycle arrest and apoptosis.
Very rare mutations reported in human tumors.•	
S149, T150, 
T155
CSN-associated •	
kinase complex
Activated in unstressed cells.•	
Promotes p53 degradation.•	
Very rare mutations reported in human tumors.•	
S315, S376, 
S378, S392
PKC, PKR, •	
GSK3β
FACT-CK2, p38 •	
kinase
CDK (cdc2/ck2), •	
AURKA
Activated by UV light (CDK/GSK3•	 β, FACT-CK2, p38 kinase), AURKA over-
expression, and interferon signaling (PKR) 
S351 phosphorylation activates p53-mediated transcription to regulate •	
apoptosis and cell cycle.
PKC constitutively phosphorylates p53 at S376 and S378 in unstressed •	
cells, IR stress leads to dephosphorylation.
S392 phosphorylation promotes sequence-specific p53 DNA binding.•	
Knockin of S392 mouse analog (S389) is phenotypically •	
normal. p53 transcriptional activation is partially compro-
mised in cells isolated from knockin mice.
Very rare mutations have been reported for individual sites •	
in human tumors.
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K120 hMOF, Tip60•	 K120 acetylation is promoted upon DNA damage.•	
Acetylation at K120 is crucial for p53-mediated apoptosis via BAX and •	
PUMA.
K120 acetylation is dispensable for cell-cycle regulation and growth arrest.•	
p53 acetylated at K120 accumulates at proapoptotic target genes.•	
K120 mutations to Arg, Glu, or Met have been reported in •	
human tumors.
Effect of K120 point mutations in animal models will need •	
to be determined.
K164 p300 / CBP•	 Acetylation is induced by DNA damage and HDAC inhibitor treatment.•	
K164 mutation does not affect DNA binding.•	
Acetylation is required for growth arrest and apoptosis.•	
Mutations of K164 are reported in human tumors.•	
K320 PCAF•	 Acetylation of K320 by PCAF is induced by DNA damage.•	
K320 acetylation increases p53 DNA-binding capability.•	
p53 K320 acetylation state effects transcriptional activity.•	
Knockin experiments of the mouse homolog K317R, mim-•	
icking p53 unacetylated at K320, enhance p53-mediated 
apoptosis after DNA damage in all cell types analyzed.
Very rare mutations reported in human tumors.•	
K370, K372, 
K373, K381, 
K382, K386
p300/CBP•	 C-terminal acetylation levels are enhanced upon stress.•	
Acetylation levels increase upon HDAC inhibitor (TSA, nicotinamide)  •	
treatment.
C-terminal acetylation enhances p53 sequence-specific DNA-binding •	
activity.
Acetylation promotes CBP/p300 recruitment and target gene activation.•	
p53 stability is affected by C-terminal acetylation due to inhibition of ubiq-•	
uitination at acetylated lysines.
p53 is deacetylated by HDACs and Sirt1.•	
Deacetylation by Sirt represses p53-dependent apoptosis in response to •	
DNA damage and oxidative stress.
Knockin experiments in mice introducing p53 with the •	
C-terminal lysines mutated (6KR/7KR) produced viable and 
phenotypically normal animals. C-terminal KR stem cells, 
MEFs, and thymocytes show normal p53 stabilization after 
DNA damage, yet p53 target gene expression is impaired in 
promoter-specific fashion.
Very rare mutations reported in human tumors.•	
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UB: K370, K372, 
K373, K381, 
K382, K386
MDM2 •	
Arf-BP1, COP1, •	
and Pirh2
MDM2-mediated polyubiquitination leads to p53 degradation.•	
monoubiquitination of p53 results in nuclear export.•	
Arf-BP1, COP1, and Pirh2 all ubiquitinate p53 and target it for proteasomal •	
degradation. 
HAUSP deubiquitinates p53 as well as regulates p53 via deubiquitination of •	
MDM2 and MDMX.
Knockin experiments in mice introducing p53 with the •	
C-terminal lysines mutated (6KR/7KR) produced viable and 
phenotypically normal animals. C-terminal KR stem cells, 
MEFs, and thymocytes display normal p53 stabilization 
after DNA damage, yet p53 target gene expression is 
impaired in a promoter-specific fashion.
Knockin experiments of the mouse homolog K317R, mim-•	
icking p53 unacetylated at K320, enhance p53-mediated 
apoptosis after DNA damage in all cell types analyzed.
Very rare mutations reported in human tumors.•	
SUMO: K386 PIAS, PIASx•	 β Functional consequences are unclear. Both activation and suppression of •	
transcriptional regulation have been reported.
NEDD8: K320 
K321, K370, 
K372, K373
FBXO11, MDM2•	 Neddylation of p53 inhibits transcriptional activity.•	
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K370 Smyd2•	 Inhibition of p53-promoter association resulting in p53 target gene •	
 repression.
Knockin experiments in mice introducing p53 with mutated •	
C-terminal lysines (6KR/7KR) produced viable and pheno-
typically normal animals. C-terminal KR stem cells, MEFs, 
and thymocytes show normal p53 stabilization after DNA 
damage, yet p53 target gene expression is impaired in 
promoter-specific fashion.
Modest effect of C-terminal lysine mutant knockins implies •	
limited effect of p53 regulation via single site metylation.
Very rare mutations reported in human tumors.•	
K372 Set7/9•	 Methylation stabilizes p53 and promotes nuclear localization to upregulate •	
p53 target gene expression.
Blocks Smyd- mediated K370 methylation.•	
K382 Set8/PR-Set7•	 Suppresses p53 mediated transcription. •	
Augments proapoptotic and checkpoint activation.•	
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O-GlcNAc: 
Ser149
O-GlcNAc  •	
transferase,  
O-GLcNAcase
Stabilization of p53 by blocking ubiquitination-mediated proteolysis.•	
Modification prevents T155 phosphorylation.•	
In vivo role of these modifications is not yet determined.•	
Very rare mutations reported in human tumors.•	
ADP-ribosylation: 
E258, D259, 
E271
PARP-1•	 ADP-ribosylation prevents p53-Crm1 interaction, resulting in nuclear ac-•	
cumulation of p53 due to inhibition of nuclear export of p53. See online version for legend and references.930 Cell 133, May 30, 2008 ©2008 Elsevier Inc. DOI 10.1016/j.cell.2008.05.020
SnapShot: p53  
Posttranslational Modifications
Jan-Philipp Kruse and Wei Gu
Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, New York, USA
Since p53 was cloned and subsequently characterized as a tumor suppressor more the 20 years ago, more than 40,000 publications have been published relating to this 
protein. A great majority of this scientific literature focuses on the intricate details of p53 regulation by posttranslational modifications. Phosphorylation, the first posttrans-
lational modification of p53 identified, was established as a positive regulator of p53 via modification at multiple sites by an ever-growing number of kinases activated by 
numerous stress signals. Subsequently, acetylation and ubiquitination have been established as major regulators of p53 by regulating p53 transcriptional activity and stabil-
ity, respectively. More recently, other modifications, such as sumoylation, neddylation, methylation, and glycosylation, have been reported. Although the cellular effects of 
many modifications are established, mouse models using site-specific knockin approaches imply that some of these modifications are to some degree redundant. These 
findings raise the possibility that aspects of the p53 posttranslational regulatory network are redundant yet indispensable for exact and precise control of p53 activity upon 
stress-induced stimulation.
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